{"id":"NCT03846453","sponsor":"HanAll BioPharma Co., Ltd.","briefTitle":"A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of 0.25% HL036 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-10","primaryCompletion":"2019-11-22","completion":"2019-11-22","firstPosted":"2019-02-19","resultsPosted":"2022-04-14","lastUpdate":"2022-04-14"},"enrollment":637,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"BIOLOGICAL","name":"HL036 Ophthalmic Solution","otherNames":["Tanfanercept"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"0.25% HL036 Ophthalmic Solution","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.","primaryOutcome":{"measure":"Coprimary Endpoint: Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 57 (Pre- to Post-CAE)","timeFrame":"Pre-CAE and Post-CAE on Day 1 (Baseline) and Day 57","effectByArm":[{"arm":"0.25% HL036 Ophthalmic Solution","deltaMin":1.38,"sd":0.427},{"arm":"Placebo","deltaMin":1.31,"sd":0.411}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1871"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":318},"commonTop":["Instillation site pain","Visual acuity reduced"]}}